BriaCell Therapeutics Corp. services

Phase I/IIa Combination Study of Bria-IMT™ with retifanlimab (INCMGA00012) and epacadostat in Advanced Breast Cancer. FDA has approved the combination study of Bria-IMT™ with Incyte Corporation’s drugs, retifanlimab and epacadostat. The combination study is listed in ClinicalTrials.gov as NCT03328026. Patients With advanced breast cancer will be eligible for combination therapy with retifanlimab and epacadostat if they have failed 2 or more prior lines of therapy.